Mechanism of Action and Efficacy of Wu-Hua-Yan-Xiao in the Treatment of Pediatric Acute Pharyngitis Based on Network Pharmacology and Experimental Validation
Drug Design, Development and Therapy · 2025
DOI: 10.2147/dddt.s513073 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Xinyun Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hunan University of Chinese Medicine, Changsha, 410208, People's Republic of China. Hauptthemen laut MEDLINE: Pharyngitis, Network Pharmacology, Drugs, Chinese Herbal, Oils, Volatile. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Ethnopharmacological Relevance: Wu-Hua-Yan-Xiao (WHYX) is an innovative volatile oil formulation derived from the traditional Yinqiao-Mabo decoction, developed for the treatment of pediatric acute pharyngitis. Materials and Methods: Network pharmacology was utilized to identify active components and potential therapeutic targets of WHYX in acute pharyngitis. Compounds in WHYX were characterized using UHPLC-QE-MS. A pediatric acute pharyngitis rat model was established by administering 25% ammonia to the pharyngeal mucosa of young rats. WHYX was delivered via aerosol inhalation at gradient concentrations. Histopathological changes in pharyngeal tissues were evaluated by H&E staining. Serum levels of IL-6, IL-1β, TNF-α, and PGE2 were quantified by ELISA. Expression levels of TNF-α, TP53, IL17A, IL6, and Bcl-2 were assessed by qRT-PCR and Western blotting. Apoptosis was analyzed through immunofluorescence staining for Caspase-3 and TUNEL.
Results
Network pharmacology identified 130 active compounds and 600 gene targets, with 194 overlapping drug-disease targets. TP53 signaling emerged as a central regulatory pathway. Compared with the model group, the high-dose WHYX volatile oil group showed marked improvements in pharyngeal pathology, significant reductions in inflammatory cytokines, downregulation of TNF-α, TP53, IL17A, IL6, and Bcl-2 expression, and suppressed apoptosis (P < 0.05). Therapeutic effects were comparable to or exceeded those observed in the positive control group. (P < 0.05).
Conclusion
The WHYX formula alleviates inflammation, reduces apoptosis, and protects pharyngeal tissue in young rats with acute pharyngitis. Aerosol inhalation of WHYX presents a direct, effective, and non-invasive strategy for pediatric acute pharyngitis management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hunan University of Chinese Medicine, Changsha, 410208, People's Republic of China.
- Research Center for Clinical Medicine, Jinshan Hospital Affiliated to Fudan University, Shanghai, 20000, People's Republic of China.
- Xiangxing College, Hunan University of Chinese Medicine, Changsha, 410208, People's Republic of China.
- Provincial Key Laboratory of TCM Diagnostics, Hunan University of Chinese Medicine, Changsha, 410208, People's Republic of China.
ORCID-Profile: Wanghua Liu, Caixing Zheng, Jinxia Li
Zitieren
APA
Zhang, X., Zhang, Z., Xu, Y., Luo, J., Shen, Z., Liang, H., Zeng, Y., Liu, W., Zheng, C., & Li, J. (2025). Mechanism of Action and Efficacy of Wu-Hua-Yan-Xiao in the Treatment of Pediatric Acute Pharyngitis Based on Network Pharmacology and Experimental Validation. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s513073
Vancouver
Zhang X, Zhang Z, Xu Y, Luo J, Shen Z, Liang H, et al. Mechanism of Action and Efficacy of Wu-Hua-Yan-Xiao in the Treatment of Pediatric Acute Pharyngitis Based on Network Pharmacology and Experimental Validation. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s513073
BibTeX
@article{Zhang2025,
author = {Zhang, Xinyun and Zhang, Zengyu and Xu, Yingzi and Luo, Jiawei and Shen, Zihao and Liang, Hao and Zeng, Yidi and Liu, Wanghua and Zheng, Caixing and Li, Jinxia},
title = {Mechanism of Action and Efficacy of Wu-Hua-Yan-Xiao in the Treatment of Pediatric Acute Pharyngitis Based on Network Pharmacology and Experimental Validation},
journal = {Drug Design, Development and Therapy},
year = {2025},
doi = {10.2147/dddt.s513073}
}
EUVIMED